SGLT-2抑制剂在美国射血分数保留的心力衰竭人群层面的影响
该决策分析模型基于2015-2018年NHANES自报心衰数据并映射GWTG-HF注册的LVEF分布,估计美国有4 794 524名成人符合SGLT-2抑制剂条件,其中2 619 248名为LVEF>40%新符合条件者。基于四项试验的NNT估计,3年内全LVEF谱可预防624 247至627 124起心衰恶化事件,LVEF>40%者可预防232 589至282 879起。
要点
- 3年内全LVEF谱可预防约62万起心衰恶化事件,LVEF>40%者占约23-28万起。
- LVEF>40%者3年内可预防约17-23万起心衰住院。
核心结论
- 在LVEF≤40%心衰获益基础上,LVEF>40%心衰患者优化SGLT-2抑制剂治疗可在美国3年内额外预防或推迟约25万起心衰恶化事件。
研究设计与样本
- 决策分析模型研究,使用2015-2018年NHANES自报心衰数据加权至全美人口,并映射GWTG-HF注册的LVEF分布。
- 纳入所有>18岁心衰患者,分为全LVEF和LVEF>40%两组,基于EMPEROR-Reduced、EMPEROR-Preserved、DAPA-HF和DELIVER试验的3年NNT估计。
主要发现
- 预计4 794 524名(95%CI 3 997 363-5 591 684)心衰成人符合SGLT-2抑制剂条件,其中2 619 248名(95%CI 2 183 759-3 054 737)为LVEF>40%新符合条件者。
- 全LVEF谱3年内可预防624 247起(95%CI 520 457-728 037)至627 124起(95%CI 522 855-731 392)心衰恶化事件。
- LVEF>40%者3年内可预防232 589起(95%CI 193 918-271 260)至282 879起(95%CI 235 846-329 912)心衰恶化事件。
- 全LVEF谱3年内可预防468 904起(95%CI 390 942-546 867)至499 110起(95%CI 416 125-582 094)心衰住院,LVEF>40%者可预防172 870起(95%CI 144 128-201 613)至231 018起(95%CI 192 608-269 428)。
临床怎么用
- 对LVEF>40%的心衰患者,应考虑使用SGLT-2抑制剂以降低心衰恶化事件和住院风险。
- 基于人群层面估计,扩大SGLT-2抑制剂在LVEF>40%心衰中的应用具有显著的公共卫生意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The expansion of sodium-glucose cotransporter-2 (SGLT-2) inhibitor use in patients with heart failure (HF) and left ventricular ejection fraction (LVEF) more than 40% following the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) and the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trials have major implications in the US. OBJECTIVE: To quantify the estimated US population-level impact of reducing worsening HF events with SGLT-2 inhibitors in individuals with LVEF more than 40%. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model study used self-reported HF data from the National Health and Nutritional Examination Survey from 2015 to 2018, which was weighted across the entire US population and subsequently mapped onto newly eligible LVEF distributions from the Get With The Guidelines-Heart Failure registry. All patients older than 18 years with HF from the National Health and Nutritional Examination Survey were grouped into the following categories: all LVEF and LVEF more than 40%. Numbers needed to treat estimations over 3 years were obtained for outcome measures from the EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction), EMPEROR-Preserved, DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), and DELIVER trials. MAIN OUTCOMES AND MEASURES: Worsening HF events (unplanned HF hospitalizations, urgent HF visits requiring intravenous therapy, or cardiovascular death). RESULTS: A projected 4 794 524 (95% CI, 3 997 363-5 591 684) adults (57% male; 67% White; mean age, 66 years) with HF would be eligible for SGLT-2 inhibitors. Of this total population, 2 619 248 (95% CI, 2 183 759-3 054 737) would be estimated as newly eligible with LVEF more than 40%. Based on estimates from the EMPEROR-Reduced/EMPEROR-Preserved and DAPA-HF/DELIVER trials, a projected 624 247 (95% CI, 520 457-728 037) to 627 124 (95% CI, 522 855-731 392) worsening HF events could be prevented across the LVEF spectrum with SGLT-2 inhibitors over 3 years, of which 232 589 (95% CI, 193 918-271 260) to 282 879 (95% CI, 235 846-329 912) events could be prevented in individuals with LVEF more than 40%. Moreover, an estimated 468 904 (95% CI, 390 942-546 867) to 499 110 (95% CI, 416 125-582 094) total HF hospitalizations could be prevented across the LVEF spectrum, of which 172 870 (95% CI, 144 128-201 613) to 231 018 (95% CI, 192 608-269 428) could be prevented in individuals with LVEF more than 40%. CONCLUSIONS AND RELEVANCE: In addition to the proven benefit in HF with LVEF of 40% and less, optimal implementation of SGLT-2 inhibitor therapy for HF with LVEF more than 40% can potentially prevent/postpone an additional approximately 250 000 worsening HF events over 3 years in the US.
引用
- Talha, Butler, Greene, et al. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. JAMA Cardiol. 2023. PMID: 36334258. doi:10.1001/jamacardio.2022.4348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。